Logo image of ISR

ISORAY INC (ISR) Stock Fundamental Analysis

NYSEARCA:ISR - NYSE Arca - US46489V1044 - Common Stock - Currency: USD

0.384  +0 (+0.03%)

Fundamental Rating

3

Taking everything into account, ISR scores 3 out of 10 in our fundamental rating. ISR was compared to 571 industry peers in the Biotechnology industry. While ISR has a great health rating, there are worries on its profitability. ISR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ISR has reported negative net income.
ISR had a negative operating cash flow in the past year.
In the past 5 years ISR always reported negative net income.
ISR had a negative operating cash flow in each of the past 5 years.
ISR Yearly Net Income VS EBIT VS OCF VS FCFISR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M

1.2 Ratios

The profitability ratios for ISR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISR Yearly ROA, ROE, ROICISR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

ISR has a Gross Margin of 40.22%. This is in the better half of the industry: ISR outperforms 78.65% of its industry peers.
ISR's Gross Margin has improved in the last couple of years.
ISR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.87%
GM growth 5Y19.43%
ISR Yearly Profit, Operating, Gross MarginsISR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100

More info and screens

9

2. Health

2.1 Basic Checks

ISR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ISR remains at a similar level compared to 1 year ago.
ISR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ISR Yearly Shares OutstandingISR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M
ISR Yearly Total Debt VS Total AssetsISR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

An Altman-Z score of 11.67 indicates that ISR is not in any danger for bankruptcy at the moment.
ISR has a better Altman-Z score (11.67) than 89.80% of its industry peers.
There is no outstanding debt for ISR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.67
ROIC/WACCN/A
WACC9.31%
ISR Yearly LT Debt VS Equity VS FCFISR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M 40M 60M

2.3 Liquidity

ISR has a Current Ratio of 14.38. This indicates that ISR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ISR (14.38) is better than 84.46% of its industry peers.
ISR has a Quick Ratio of 13.99. This indicates that ISR is financially healthy and has no problem in meeting its short term obligations.
ISR has a better Quick ratio (13.99) than 83.52% of its industry peers.
Industry RankSector Rank
Current Ratio 14.38
Quick Ratio 13.99
ISR Yearly Current Assets VS Current LiabilitesISR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ISR have decreased strongly by -20.00% in the last year.
The Revenue has decreased by -2.79% in the past year.
ISR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.79% yearly.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-2.79%
Revenue growth 3Y13.86%
Revenue growth 5Y17.79%
Sales Q2Q%-33.03%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year44.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ISR Yearly Revenue VS EstimatesISR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ISR Yearly EPS VS EstimatesISR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ISR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISR Price Earnings VS Forward Price EarningsISR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISR Per share dataISR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ISORAY INC

NYSEARCA:ISR (2/17/2023, 8:04:00 PM)

0.384

+0 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-28 2022-09-28/amc
Earnings (Next)N/A N/A
Inst Owners2.86%
Inst Owner Change1%
Ins Owners0.37%
Ins Owner Change0%
Market Cap107.00M
Analysts83.33
Price Target1.02 (165.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)0.99%
Max EPS beat(2)0.99%
EPS beat(4)1
Avg EPS beat(4)-21.01%
Min EPS beat(4)-32.01%
Max EPS beat(4)0.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.78%
Min Revenue beat(2)-12.78%
Max Revenue beat(2)-12.78%
Revenue beat(4)0
Avg Revenue beat(4)-8.56%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)-5.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)9.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)13.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.76
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.86
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.04
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.22%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.87%
GM growth 5Y19.43%
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 108.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.38
Quick Ratio 13.99
Altman-Z 11.67
F-Score3
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)158.12%
Cap/Depr(5y)198.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-1%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.79%
Revenue growth 3Y13.86%
Revenue growth 5Y17.79%
Sales Q2Q%-33.03%
Revenue Next Year44.05%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-112.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.16%
OCF growth 3YN/A
OCF growth 5YN/A